Cancer is the 2^nd most fatal disease around the globe. Various receptors have been showed to be overexpressed and/or mutated in numerous cancers. Discoidin domain receptors 1 (DDR1) and 2 (DDR2) are one of the novel receptor tyrosine kinases (RTKs), which have been proved to regulate various cellular signaling pathways, cell proliferation, adhesion, migration, matrix remodeling, and dysregulation of these receptors may lead to metastatic cancer progressions. These receptors belong to unique category of RTKs, which require collagen binding for its activation. Yet the mechanism of this extracellular collagen binding and activation of cytosolic kinase domain of the receptors is not clear. Like other RTKs, these receptors also showed its extensive implications in numerous cancers like lung, breast, ovarian, pancreatic cancer and many others. Therefore DDR1 and DDR2 emerge as potential therapeutic targets in preventing cancer. Various small molecule tyrosine kinase inhibitors have been developed against these two receptors and proved to be highly efficacious in reducing tumor progressions. This review would highlight the detailed structure, functions, mechanism of action, signaling pathways of DDR1 and DDR2, their roles in cancer developments and the inhibition of these receptors with numerous inhibitors can be a promising strategy to combat this hefty menace.

癌症是^第二全球最致命的疾病。在多种癌症中，各种受体已显示出过表达和/或突变。Discoidin域受体1（DDR1）和2（DDR2）是新型受体酪氨酸激酶（RTK）之一，已被证明可调节这些受体的各种细胞信号通路，细胞增殖，粘附，迁移，基质重塑和失调。可能导致转移性癌症进展。这些受体属于RTK的独特类别，其需要胶原蛋白结合才能激活。这种细胞外胶原结合和受体胞质激酶结构域活化的机制尚不清楚。像其他RTK一样，这些受体在许多癌症（如肺癌，乳腺癌，卵巢癌，胰腺癌和许多其他癌症）中也显示出广泛的意义。因此，DDR1和DDR2成为预防癌症的潜在治疗靶标。已经针对这两种受体开发了各种小分子酪氨酸激酶抑制剂，并被证明在减少肿瘤进展方面非常有效。这篇综述将重点介绍DDR1和DDR2的详细结构，功能，作用机理，信号传导途径，它们在癌症发展中的作用以及用多种抑制剂抑制这些受体，这可能是对抗这种严重威胁的有前途的策略。